| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UGT1A10 |
| Uniprot No | Q9HAW8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-530 aa |
| 活性数据 | MARAGWTSPVPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMQSVVEKLILRGHEVVVVMPEVSWQLERSLNCTVKTYSTSYTLEDQNREFMVFAHAQWKARAQSIFSLLMSSSSGFLDLFFSHCRSLFNDRKLVEYLKESSFDAVFLDPFDTCGLIVAKYFSLPSVVFTRGIFCHHLEEGAQCPAPLSYVPNDLLGFSDAMTFKERVWNHIVHLEDHLFCQYLFRNALEIASEILQTPVTAYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH |
| 分子量 | 84.04 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人UGT1A10蛋白的参考文献示例，包含文献名称、作者及摘要概述：
1. **"Substrate specificity of human UDP-glucuronosyltransferase 1A10"**
*Nakamura et al. (2008)*
摘要：本研究通过体外重组表达系统，比较了UGT1A10与其他UGT同工酶的底物代谢特性，发现其对黄酮类化合物和部分抗癌药物(如SN-38)具有高催化活性，强调了其在肠道组织药物代谢中的潜在作用。
2. **"Structural determinants of UGT1A10 activity studied by homology modeling and site-directed mutagenesis"**
*Mazerska et al. (2015)*
摘要：通过同源建模和突变分析，探讨了重组UGT1A10的三维结构特征，确定了关键氨基酸残基对其催化功能的影响，揭示了底物结合口袋的构效关系。
3. **"Epigenetic regulation of UGT1A10 expression by promoter methylation in human colon cancer cells"**
*Chen et al. (2012)*
摘要：研究发现结肠癌细胞中UGT1A10的低表达与其启动子区域高甲基化相关，重组UGT1A10的表达恢复可增强抗癌药物的代谢敏感性，提示表观遗传调控在其功能中的作用。
4. **"Recombinant UGT1A10 as a tool for predicting drug disposition in the gastrointestinal tract"**
*Singh et al. (2016)*
摘要：利用重组UGT1A10模型评估了多种口服药物的葡萄糖醛酸化代谢，验证其在预测肠道首过代谢及个体化用药中的应用潜力。
(注：上述文献信息为示例性概括，实际引用需核实具体文献内容及作者发表信息。)
UGT1A10 is a member of the uridine diphosphate (UDP)-glucuronosyltransferase (UGT) enzyme superfamily, which plays a critical role in the metabolic detoxification and elimination of both endogenous compounds (e.g., bilirubin, steroids) and xenobiotics (e.g., drugs, environmental toxins). As part of the UGT1A subfamily, UGT1A10 is encoded by the UGT1A gene complex on chromosome 2q37. Unlike hepatic UGT isoforms (e.g., UGT1A1), UGT1A10 is predominantly expressed in extrahepatic tissues, particularly the gastrointestinal tract, including the stomach, small intestine, and colon, as well as in steroid-target tissues like the mammary gland. This localization suggests its specialized role in first-pass metabolism of orally administered drugs and detoxification of dietary carcinogens.
UGT1A10 catalyzes the transfer of glucuronic acid to hydrophobic substrates, enhancing their water solubility for excretion. It metabolizes a broad spectrum of substrates, including phenols, flavonoids, and clinically relevant drugs like opioids and estrogens. Polymorphisms in UGT1A10 have been linked to interindividual variability in drug responses and cancer susceptibility. Recombinant UGT1A10 protein, produced via heterologous expression systems (e.g., HEK293 cells, baculovirus-insect cells), is widely used in vitro to study enzyme kinetics, substrate specificity, and drug-drug interactions, aiding drug development and personalized medicine strategies. Its structural features, including a conserved C-terminal catalytic domain and variable N-terminal substrate-binding region, underlie its functional diversity. Research continues to explore its roles in chemoprevention, hormonal regulation, and tissue-specific detoxification pathways.
×
